Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically documented gastric or gastroesophageal junctional adenocarcinoma (not amenable to curative therapy)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Adequate hematological, liver and kidney function. Measurable or non-measurable, but evaluable disease using RECIST v1.1~* Fibroblast growth factor receptor 2b (FGFR2b) overexpression as determined by a centrally performed immunohistochemistry tissue test and/or FGFR2 gene amplification as determined by a centrally performed circulating tumor deoxyribonucleic acid (ctDNA) blood based assay~* Candidate for mFOLFOX6 chemotherapy~Key Exclusion Criteria:~* Untreated or symptomatic central nervous system (CNS) metastases~* Clinically significant cardiac disease,~* Peripheral sensory neuropathy \>/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2~* Active infection requiring systemic treatment~* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection~* Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway~* Known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer~* Known positivity for human epidermal growth factor receptor 2 (HER2)~* Women who are pregnant or breastfeeding~Note: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bemarituzumab + mFOLFOX6 (Type: EXPERIMENTAL): Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
- Placebo + mFOLFOX6 (Type: PLACEBO_COMPARATOR): Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).